February 2026 in “NeuroSci” This systematic review synthesizes evidence on the distribution of 5a-reductase isozymes and their implications for mental health, finding that inhibition of neurosteroidogenesis may contribute to anxiety, depression, and suicidality, with some patients experiencing persistent psychiatric effects from finasteride or dutasteride.
February 2026 in “The Journal of Sexual Medicine” In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.
January 2025 in “Heliyon” This study found no significant difference in the risk of poor glycemic control between men with type 2 diabetes using tamsulosin and those using finasteride.
November 2024 in “Singapore Medical Journal” A bladder rupture from prostate treatment was healed with catheterization and antibiotics.
November 2023 in “Brain Sciences” This study investigated medications potentially linked to male-factor infertility using the FDA Adverse Event Reporting System and found that finasteride, testosterone, valproate, and other drugs showed significant disproportionate reporting of infertility cases, highlighting a potential under-reporting issue to regulatory bodies.
March 2023 in “Translational Andrology and Urology” This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.
January 2020 in “Journal of Men s Health” In this study of BPH patients with testosterone deficiency, the combination of TU and dutasteride reduced prostate volume and improved testosterone-related symptoms but was less effective for sexual function compared to TU alone, indicating caution in using dutasteride for those with sexual dysfunction concerns.
March 2014 in “Hair transplant forum international” This article discusses the evolving field of hair transplantation surgery and reports no new experimental results, highlighting ongoing developments aimed at improving procedural success and doctor efficacy.
November 2012 in “Endocrine Practice” This review outlines the physiological roles of 5a-reductases and highlights the need for further research to better understand their function and minimize adverse effects from their inhibitors used in treatment.
May 2026 in “Nature Communications” In this study, researchers identified that keloid fibroblasts respond to neurotransmitters from catecholaminergic nerves by producing bone matrix proteins, mediated by β1-adrenergic receptor activation, leading to fibro-osseous reprogramming; blocking this signaling in a rodent model prevented the development of keloid-like pathology.
December 2024 in “International Journal of Molecular Sciences” This study observed that CXCL12 is highly co-expressed with androgen receptors in human hair follicle cells, and its inhibition via antibodies increased hair length, suggesting a potential treatment strategy for androgenic alopecia.
January 2023 in “Andrologia” This study found that American men undergoing fertility evaluation are older, more obese, and experience longer infertility durations than their Canadian counterparts, with potentially reversible factors being more prevalent in the US.
January 2023 in “International Journal of Molecular Sciences” This study found that a double-crosslinked hydrogel using GelMA and sulfhydrylated chitosan showed promising results in healing full-thickness skin wounds in rats by accelerating tissue repair and promoting collagen and blood vessel formation.
86 citations
,
December 2002 in “Tissue Antigens” In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.
August 2026 in “Dermatology and Therapy” This study in the United Arab Emirates found that alopecia areata significantly impacts patient quality of life and healthcare resource utilization, particularly among those with higher scalp hair loss.
4 citations
,
July 2024 in “The Journal of Dermatology” This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.
July 2026 in “Journal of the American Academy of Dermatology”
1 citations
,
October 2019 in “Proceedings Mulawarman Pharmaceuticals Conference” This study observed that aloe vera serum was comparable to minoxidil in promoting hair growth over 21 days but had no effect on sun protection.
1 citations
,
September 2023 in “Meditsinskiy sovet = Medical Council” In this study involving children with alopecia areata, researchers found that adding narrowband UVB 311 nm therapy to standard treatment significantly improved hair regrowth in those with coexisting atopic dermatitis compared to those without the condition.
March 2026 in “JID Innovations” In a mouse model study, researchers found that mutations in Aire reduced alopecia areata frequency, while Notch4 mutations did not lead to the disease, likely due to proximity with a resistance gene.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” This study found that ultraviolet-induced fluorescence dermoscopy enhanced the identification of follicular openings in alopecia areata, potentially aiding in the assessment of disease severity and treatment strategies.
August 2025 in “Academic International Journal of Veterinary Medicine” In this experimental study on rabbits, researchers found that while aloe vera extract did not change the visible wound healing rate, it enhanced histological recovery, promoting early re-epithelialization and minimal inflammation, indicating superior tissue regeneration compared to untreated wounds.
June 2025 in “Revista Foco” This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.
11 citations
,
September 2013 in “Journal of The European Academy of Dermatology and Venereology” In this study, sensorineural hearing loss was significantly more frequent in patients with alopecia areata compared to healthy controls, suggesting a relationship between the autoimmune condition and hearing function.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
60 citations
,
February 2015 in “Biomaterials” In this study, immobilized VEGF selectively captured endothelial cells under various shear stresses, suggesting its potential for promoting endothelialization in vascular grafts or implanted tissues.
14 citations
,
January 2014 in “Anais Brasileiros de Dermatologia” This study found that low BMI may increase the risk of developing chilblains in individuals exposed to cold weather, with many patients experiencing recurrent lesions each winter.
3 citations
,
March 2022 in “Medicine” This case report described a patient with unilateral branch retinal artery occlusion due to previously undiagnosed systemic lupus erythematosus, where systemic immunotherapy led to significant visual improvement and resolution of macular edema.
September 2025 in “Obstetrics and gynecology.” This review examines the pathophysiology of PCOS and reports that myoinositol may improve menstrual regularity, insulin sensitivity, and reproductive outcomes, with comparable efficacy to metformin and often better tolerability.
November 2021 in “Journal of The American Academy of Dermatology” This study found that advanced stages of female pattern hair loss are associated with increased age, menopausal state, and hypertension, while acne vulgaris is more prevalent in earlier stages.